| Outcome Measures: |
Primary: Change in plasma ANP level at 1 Day, +16.72 pg/mL, P = 0.24, 95% CI \[-12.1, +45.5\] at 2 hours, Change from Baseline compared in plasma ANP following 1 dose of liraglutide (0.6 mg) compared to crossover treatment with placebo at the 2-hour timepoint|Change in plasma ANP level at 21 Days, -17.42 pg/mL, 95% CI \[-36.0, +1.21\] at 2 hours, Change from Baseline in plasma ANP following 21 days of liraglutide (titrated to 1.8 mg) compared to crossover treatment with placebo at the 2-hour timepoint | Secondary: Change in mean 24-Hr urinary sodium excretion rate following 21 days of liraglutide (titrated 1.8mg) compared to crossover with placebo (baseline-subtracted), median change +14.18 mmol/L liraglutide vs. placebo (statistically significant, Wilcoxon rank sum), 21 days|Change in mean Nighttime urinary sodium excretion rate following 21 days of liraglutide (titrated 1.8mg) compared to crossover with placebo (baseline-subtracted), median change +4.24 mmol/L nighttime, liraglutide vs. placebo (statistically significant, Wilcoxon Rank Sum), 21 days|Change in mean 24-Hr systolic BP, liraglutide compared to crossover with placebo (baseline-subtracted), +2.33 ± 1.67, p=0.18;Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days|Change in mean 24-hr diastolic BP, liraglutide compared to crossover with placebo (baseline-subtracted), +3.78 ± 1.34, p=0.01;Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days|Change in mean 24-hr HR, liraglutide compared to crossover with placebo (baseline-subtracted), +5.21 ± 2.42, p=0.05; Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days|Office-measured systolic BP; Treatment difference for liraglutide compared to crossover with placebo, -2.35 mmHg (3.49), p=0.51;Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days|Office-measured diastolic BP;Treatment difference for liraglutide compared to crossover with placebo, +3.6 mmHg (2.33), p=0.14;Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days|Office-measured heart rate;Treatment difference for liraglutide compared to crossover with placebo, +9.25 (3.51), p=0.02;Treatment difference liraglutide (1.8 mg) vs. placebo LSMD (±SE), p value, 21 days | Other: Change in HbA1c%, -0.7%, p=0.005; least squares mean difference, liraglutide compared placebo, 21 days|Change in Fasting Blood Glucose, -3.4 mmol/L, p=0.0004; least squares mean difference, liraglutide compared to crossover with placebo, p-value, 21 days|Change in Total Cholesterol, -0.63 mmol/L, p=0.002; least squares mean difference, liraglutide compared to crossover with placebo, p-value, 21 days|Change in LDL Cholesterol, -0.37 mmol/L, p=0.04; least squares mean difference, liraglutide compared to crossover with placebo, p-value, 21 days|Change in eGFR (estimated Glomerular Filtration Rate), -5.76 ml/min/1.73m2 (2.60), p=0.04; least squares mean difference, liraglutide compared to crossover with placebo, (SE), p-value, 21 days|Change in Body Weight, +1.35 Kg (0.46), p=0.009; least squares mean difference (SE), p-value, liraglutide compared to crossover with placebo, 21 days|Change in BMI (Body Mass Index), -0.42 Kg/cm2 (0.18), p=0.03; least squares mean difference (SE), p-value, liraglutide compared to crossover with placebo, 21 days|Change in Plasma Angiotensin II, -0.97 pmol/L (0.86), p=0.28; least squares mean difference (SE), p-value, liraglutide compared to placebo, 21 days|Change in Plasma CRP, 0.09 mg/L (0.80), p=0.91; least squares mean difference (SE), p-value, liarglutide compared to placebo, 21 days|Change in Triglycerides, -0.2 mmol/L (0.18), p=0.28;least squares mean difference (SE), p-value, liarglutide compared to placebo, 21 days|Change in HDL, +0.083 mmol/L (0.03), p=0.02;least squares mean difference (SE), p-value, liarglutide compared to placebo, 21 days
|
